摘要：
Objective To study the possible relationship between the output of new products in China’s pharmaceutical industry and the investment in research and development (R&D), and to provide a theoretical basis for the decision-making of relevant enterprises and institutions. Methods The econometric software Stata 14 was used to perform unit root test on the relevant data. Then, a co-integration regression equation was established after stabilization, which was analyzed through co-integration test (E-G two-step method). Results and Conclusion There is a long-term equilibrium and short-term error correction relationship between the output of new products and the investment of R&D funds in China’s pharmaceutical industry. During the lagging periods from 1 to 6, R&D investment is the Granger reason for the output of new products. The investment of R&D funds has a positive effect on the output of new products and the effect is significant. Therefore, more investment should be made in R&D to enhance the output of new products.
Li Gan, Wang Su, Chen Yuwen.
Co-integration Analysis of the Relationship between New Product Output and R&D Investment in China’s Pharmaceutical Industry
[J]. 亚洲社会药学, 2022, 17(4): 309-316.
Li Gan, Wang Su, Chen Yuwen. Co-integration Analysis of the Relationship between New Product Output and R&D Investment in China’s Pharmaceutical Industry[J]. Asian Journal of Social Pharmacy, 2022, 17(4): 309-316.
